Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has recently been developed for patients with predicted insufficient future liver remnant volumes to induce more rapid hepatic hypertrophy and increase resectability. In the medical literature, the use of ALPPS in hepatocellular carcinoma (HCC) has rarely been reported.
Introduction
Trisectionectomy has been associated with higher complication rates and increased postoperative liver dysfunction/failure than liver resections involving lesser volumes. Preoperative portal vein embolization (PPVE) and portal vein ligation (PVL) have been used to induce hepatic hypertrophy of future liver remnant and to reduce the risk of post-hepatectomy liver failure in patients who have insufficient future liver remnants. 1, 2 To induce more rapid hepatic hypertrophy and to increase resectability, associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has recently been developed. This technique was first carried out by Dr. Hans Schlitt from Regensburg in 2007 and it was first presented in a German Congress in 2010. 3 The procedure requires liver parenchymal transection just to the right of the umbilical fissure with simultaneous right portal vein ligation during the first stage of the operation, followed about one to two weeks later by completion right trisectionectomy. The novelty of ALPPS is the marked percentage gain of patients to resectability. To the best of our knowledge, no prospective studies comparing traditional methods (PPVE, PVL or two staged hepatectomy strategy) with ALPPS are now available. The retrospective study of Schadde et al. showed the extrapolated growth rate in ALPPS was 11 times higher (34.8 ml/day) than PPVE/PVL (3 ml/day). 4 Despite the sudden increase in reports on ALPPS during the last 2 years, a lot of questions concerning the safety and effectiveness of ALPPS remained unanswered. Currently, ALPPS is still considered to be in an early development phase, and its indications and techniques are not standardized.
In the literature, the use of ALPPS in hepatocellular carcinoma (HCC) has rarely been reported. The majority of reports were on colorectal liver metastases and hilar cholangiocarcinoma arising in normal livers. We reported the use of ALPPS in a patient with a large HCC with hepatitis B related liver fibrosis. 
Presentation of case
A 55-year-old male presented with epigastric discomfort and recent weight loss of 4.5 kg. He had a history of hepatitis B related cirrhosis and a history of splenectomy for traumatic injury many years ago. His contrast enhanced computed tomography (CT) showed 2 large conglomerated tumors, one measuring 16 cm × 10.5 cm in segments 5, 6, 7 and 8, and another 4 cm in segment 4. There were at least 3 satellite nodules around the main tumor, with the largest one measuring 3 cm. His liver function showed bilirubin, 7 mol/L; albumin, 31 g/L; prothrombin time, 13.5-s; creatinine, 77 mol/L; hemoglobin, 14.1 g/dL; platelet count, 435 × 10 9 L −1 . Indocyanine green retention rate at 15 min (ICG-R15) was 9.3%. Alpha-fetoprotein (AFP) level was 3044 ng/ml. Entecavir (Baraclude) was started before the operation.
Procedure: upper midline incision was used in the first operation
At the first operation only the round ligament and the falciform ligament were divided and both sides of the liver were not mobilized. A thorough exploration and intraoperative ultrasound (IOUS) were used to assess and stage the liver tumors. Cholecystectomy was performed before the right hilar dissection. The right portal vein was ligated with strong silk tie and was not divided. The right hepatic artery and the right hepatic duct were identified, were not isolated separately, and marked with vessel loops. Liver parenchymal transection was carried out on the right side of the falciform ligament using a CUSA (Cavitron Ultrasonic Surgical Aspirator). The segment 4 pedicles were transected with endostaplers. A leak test was performed via the cystic duct and it confirmed no bile leakage in the liver transection plane. No wrapping/interposition material at the transection surface was used. A silicone drain was inserted near the transection surface (Fig. 1a-c) .
After CT scan with volumetric assessment, the second phase of the operation was performed 14 days after the first operation. In the second operation, a right transverse abdominal incision was added in addition to the midline incision in the first operation. The right liver was then mobilized from the inferior vena cava (IVC), and all the retrohepatic veins draining the right liver were ligated and divided. The right hepatic duct, right portal vein, right hepatic artery, right hepatic vein and middle hepatic vein were divided with endostaplers and the tumor-bearing liver was removed with a 11.5 cm × 6 cm patch of diaphragm. The diaphragm was repaired directly without any mesh. A 16Fr chest drain was inserted (Fig. 2a-c) . No Pringle maneuver was needed during these two operations.
Volumetric assessment
CT scan with volumetry assessment was performed before the first operation and at completion of surgery. 3-Dimensional (3D) CT scan reconstruction was also performed using Yortal 3D reconstruction system (Yortal Digital Medical Imaging Tech Co. Ltd., China). The preoperative remnant liver volume to total liver volume ratio (RLV/TLV) ratio was 26.9%. After 8 days, the RLV/TLV ratio increased to 37.4%. The FLV (segments 2, 3 and part of segment 1) increased from 383 ml to 532 ml (Figs. 3a-c and 4a-c) .
Operative parameters and post-operative course
At the first operation, the operating time was 231 min, and blood loss was 500 ml. At the second operation, the operating time was 198 min, and blood loss was 700 ml. No perioperative blood transfusion was needed. The patient resumed oral diet intake on post-operative day 2 after the first and the second operations. He had a transient increase in drain output of ascitic fluid after the second operation, which subsided with medical treatment. His liver function recovered gradually and he had no bile leak. The patient was discharged home on postoperative day 13 after the second operation.
Histopathology
Histopathology confirmed a 16.5 cm × 10.5 cm × 18 cm HCC in the right liver and a 3.2 cm HCC in segment 4, with Edmondson & Steiner grade 3 and pT3a. These were extensive tumor necrosis and presence of microscopic vascular invasion but no definite portal vein tumor thrombus. The resection margins were clear. The liver parenchyma showed chronic hepatitis changes with bridging fibrosis.
Follow-up
Follow-up CT scan at 6 weeks after the second operation showed further hypertrophy of the liver remnant. There was no recurrence (Fig. 5) . He remained well at 2 months after the ALPPS. The AFP level at 6 weeks after operation was 6 ng/ml.
Discussion
ALPPS has been adopted all over the world in the past 2 years, even though the oncological long-term results remain unknown, and benefit for patients is still questionable. Even if the oncologic outcomes are acceptable, it remains controversial whether the gain in quality of life and survival could balance the high risks of complication and mortality. The current evidence suggested that ALPPS offered a better chance of complete resection in patients who had primarily unresectable liver tumors at the cost of high operation morbidity and mortality. The morbidity rate has been reported to be as high as 70%, with high rates of procedure-related deaths of about 15%. [4] [5] [6] [7] [8] [9] Bile leakage from the raw surface of the liver and septic events secondary to ischemic necrosis of liver were the most common complications. Another major question which remained unanswered is whether stimulation of liver hypertrophy could also accelerate tumor progression. This is a question which has been debated since the time of PPVE/PVL techniques. Many reports showed accelerated tumor growth after PPVE is of major concern and requires consideration of post-PVE chemotherapy. 10, 11 Thus, ALPPS also has a potential to promote tumor recurrence and progression. Recently, Oldhafer et al. reported that for the 10 patients with unresectable colorectal liver metastases who underwent ALPPS, 6 of the 7 patients who had a follow-up of at least 3 months developed tumor recurrence in the liver. In addition, 3 of the 7 patients developed lung metastases, which appeared earlier than the liver metastases in 2 of the 3 patients. The remaining patient with a follow-up of 3 months had no radiological recurrent disease, but had increasing carcinoembryonic antigen (CEA) levels. 12 Whether the rapid hypertrophy itself promotes tumor recurrence remains uncertain and this requires further investigation.
Several series in the medical literature described a median of 74-110% increase in FRL volume at a median of 9-15 days between the 2 steps of the operation. [4] [5] [6] [7] [8] [9] These livers were mainly normal liver. Our case showed that this novel strategy was feasible even with a chronic hepatitis B related liver fibrosis, although the hypertrophy rate was slower and the time frame needed for the 2 stages of operation was longer.
In conclusion, ALPPS is also feasible in hepatitis B related liver fibrosis. It gives a hope of cure for patients with unresectable disease. More studies are needed to further evaluate its effectiveness and oncological outcomes.
